|
Liposomal doxorubicin Clinical Trials
5 actively recruiting trials across 5 locations
No change since May 2026
Also known as: Caelyx, DOX, DOXIL®, Doxil®, Lipodox
Pipeline
Phase 1: 1Phase 2: 2Phase 3: 2
Top Sponsors
- Merck Sharp & Dohme LLC2
- Northwestern University1
- Memorial Sloan Kettering Cancer Center1
- H. Lee Moffitt Cancer Center and Research Institute1
Indications
- Cancer5
- Breast Neoplasms2
- Breast Cancer2
- Metastatic Ewing Sarcoma1
- Relapsed or Refractory Hodgkin Lymphoma1
Birmingham, Alabama1 trial
Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes
University of Alabama at Birmingham (Children's of Alabama)
Phase 1
Daphne, Alabama1 trial
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Southern Cancer Center (SCC) ( Site 8000)
Phase 3
Chandler, Arizona1 trial
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Ironwood Cancer & Research Centers ( Site 0066)
Phase 3
Duarte, California1 trial
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
City of Hope Cancer Center (Data Collection Only)
Phase 2
Chicago, Illinois1 trial
Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
Northwestern University
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.